<?xml version='1.0' encoding='utf-8'?>
<document id="32175680"><sentence text="Two high-performance liquid chromatography-tandem mass spectrometry methods for determination of edaravone and taurine in human plasma: Application to drug-drug interaction and pharmacokinetic studies."><entity charOffset="97-106" id="DDI-PubMed.32175680.s1.e0" text="edaravone" /><entity charOffset="111-118" id="DDI-PubMed.32175680.s1.e1" text="taurine" /><pair ddi="false" e1="DDI-PubMed.32175680.s1.e0" e2="DDI-PubMed.32175680.s1.e0" /><pair ddi="false" e1="DDI-PubMed.32175680.s1.e0" e2="DDI-PubMed.32175680.s1.e1" /></sentence><sentence text="Two high-performance liquid chromatography-tandem mass spectrometry methods were developed and validated for the quantification of edaravone (method A) or taurine (method B) in human plasma"><entity charOffset="131-140" id="DDI-PubMed.32175680.s2.e0" text="edaravone" /><entity charOffset="155-162" id="DDI-PubMed.32175680.s2.e1" text="taurine" /><pair ddi="false" e1="DDI-PubMed.32175680.s2.e0" e2="DDI-PubMed.32175680.s2.e0" /><pair ddi="false" e1="DDI-PubMed.32175680.s2.e0" e2="DDI-PubMed.32175680.s2.e1" /></sentence><sentence text=" After protein precipitation, separations were achieved on an Ultimate XB-C8 (2" /><sentence text="1 × 50 mm, 3" /><sentence text="0 µm) column for edaravone and a ZORBAX SB-Aq column (2"><entity charOffset="17-26" id="DDI-PubMed.32175680.s5.e0" text="edaravone" /></sentence><sentence text="1 × 100 mm, 3" /><sentence text="5 µm) for taurine, respectively"><entity charOffset="10-17" id="DDI-PubMed.32175680.s7.e0" text="taurine" /></sentence><sentence text=" The detection used electrospray ionization source via multiple reaction monitoring in positive-ion mode for edaravone and negative-ion mode for taurine, respectively"><entity charOffset="109-118" id="DDI-PubMed.32175680.s8.e0" text="edaravone" /><entity charOffset="145-152" id="DDI-PubMed.32175680.s8.e1" text="taurine" /><pair ddi="false" e1="DDI-PubMed.32175680.s8.e0" e2="DDI-PubMed.32175680.s8.e0" /><pair ddi="false" e1="DDI-PubMed.32175680.s8.e0" e2="DDI-PubMed.32175680.s8.e1" /></sentence><sentence text=" The lower limits of quantification were 10" /><sentence text="0 ng/mL for edaravone and 3"><entity charOffset="12-21" id="DDI-PubMed.32175680.s10.e0" text="edaravone" /></sentence><sentence text="00 μg/mL for taurine"><entity charOffset="13-20" id="DDI-PubMed.32175680.s11.e0" text="taurine" /></sentence><sentence text=" The selectivity, accuracy, and precision of the methods were all within acceptable limits" /><sentence text=" Two methods were successfully applied to a drug-drug interaction study and a pharmacokinetic study of edaravone and taurine in healthy Chinese volunteers after intravenous infusion of single or compound injection"><entity charOffset="103-112" id="DDI-PubMed.32175680.s13.e0" text="edaravone" /><entity charOffset="117-124" id="DDI-PubMed.32175680.s13.e1" text="taurine" /><pair ddi="false" e1="DDI-PubMed.32175680.s13.e0" e2="DDI-PubMed.32175680.s13.e0" /><pair ddi="false" e1="DDI-PubMed.32175680.s13.e0" e2="DDI-PubMed.32175680.s13.e1" /></sentence><sentence text=" The results showed that co-administration of edaravone with taurine increased the Cmax and AUC0-24 of taurine in human plasma while taurine did not affect the systemic exposure of edaravone"><entity charOffset="46-55" id="DDI-PubMed.32175680.s14.e0" text="edaravone" /><entity charOffset="61-68" id="DDI-PubMed.32175680.s14.e1" text="taurine" /><entity charOffset="103-110" id="DDI-PubMed.32175680.s14.e2" text="taurine" /><entity charOffset="133-140" id="DDI-PubMed.32175680.s14.e3" text="taurine" /><entity charOffset="181-190" id="DDI-PubMed.32175680.s14.e4" text="edaravone" /><pair ddi="false" e1="DDI-PubMed.32175680.s14.e0" e2="DDI-PubMed.32175680.s14.e0" /><pair ddi="false" e1="DDI-PubMed.32175680.s14.e0" e2="DDI-PubMed.32175680.s14.e1" /><pair ddi="false" e1="DDI-PubMed.32175680.s14.e0" e2="DDI-PubMed.32175680.s14.e2" /><pair ddi="false" e1="DDI-PubMed.32175680.s14.e0" e2="DDI-PubMed.32175680.s14.e3" /><pair ddi="false" e1="DDI-PubMed.32175680.s14.e0" e2="DDI-PubMed.32175680.s14.e4" /><pair ddi="false" e1="DDI-PubMed.32175680.s14.e1" e2="DDI-PubMed.32175680.s14.e1" /><pair ddi="false" e1="DDI-PubMed.32175680.s14.e1" e2="DDI-PubMed.32175680.s14.e2" /><pair ddi="false" e1="DDI-PubMed.32175680.s14.e1" e2="DDI-PubMed.32175680.s14.e3" /><pair ddi="false" e1="DDI-PubMed.32175680.s14.e1" e2="DDI-PubMed.32175680.s14.e4" /><pair ddi="false" e1="DDI-PubMed.32175680.s14.e2" e2="DDI-PubMed.32175680.s14.e2" /><pair ddi="false" e1="DDI-PubMed.32175680.s14.e2" e2="DDI-PubMed.32175680.s14.e3" /><pair ddi="false" e1="DDI-PubMed.32175680.s14.e2" e2="DDI-PubMed.32175680.s14.e4" /><pair ddi="false" e1="DDI-PubMed.32175680.s14.e3" e2="DDI-PubMed.32175680.s14.e3" /><pair ddi="false" e1="DDI-PubMed.32175680.s14.e3" e2="DDI-PubMed.32175680.s14.e4" /></sentence><sentence text=" Edaravone and taurine have the dose-dependent pharmacokinetic profiles in human"><entity charOffset="1-10" id="DDI-PubMed.32175680.s15.e0" text="Edaravone" /><entity charOffset="15-22" id="DDI-PubMed.32175680.s15.e1" text="taurine" /><pair ddi="false" e1="DDI-PubMed.32175680.s15.e0" e2="DDI-PubMed.32175680.s15.e0" /><pair ddi="false" e1="DDI-PubMed.32175680.s15.e0" e2="DDI-PubMed.32175680.s15.e1" /></sentence><sentence text="" /></document>